Shares of 9 Meters Biopharma, Inc. (NASDAQ:NMTR – Get Rating) have been given an average rating of “Moderate Buy” by the six ratings firms that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $58.33.
Separately, Citigroup began coverage on 9 Meters Biopharma in a research note on Monday, February 13th. They issued a “neutral” rating on the stock.
9 Meters Biopharma Stock Performance
NMTR stock opened at $1.36 on Friday. The company has a quick ratio of 1.43, a current ratio of 1.43 and a debt-to-equity ratio of 1.17. The business’s fifty day simple moving average is $2.04 and its two-hundred day simple moving average is $2.69. 9 Meters Biopharma has a twelve month low of $1.00 and a twelve month high of $13.20. The firm has a market cap of $17.61 million, a price-to-earnings ratio of -0.44 and a beta of 0.51.
Institutional Trading of 9 Meters Biopharma
9 Meters Biopharma Company Profile
9 Meters Biopharma, Inc is a clinical-stage biopharmaceutical company, which focuses on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. The company is founded by Jay P.
- Get a free copy of the StockNews.com research report on 9 Meters Biopharma (NMTR)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Receive News & Ratings for 9 Meters Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 9 Meters Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.